A — A multicenter randomized trial found no significant differences in response rates, time to progression, or overall survival between first-line single-agent mitoxantrone and combination FEC chemotherapy in high-risk metastatic breast cancer patients, indicating comparable efficacy ([Heidemann, 2002, 12419743]).